Aptevo Therapeutics Inc. (APVO)
After hours:
- ACCESSWIRE
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended March 31, 2022.
- ACCESSWIRE
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant DiseaseSEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the presentation of preclinical data for APVO442 in a poster session at the American
- ACCESSWIRE
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible StatusSEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. This follows the Company's previous announcement that a patient receiving combination therapy is also moving to transplant after one cycle of therapy.
